Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
List view / Grid view
Filter the results
A new technology called mass cytometry, or CyTOF, is providing new insights into a range of key proteins in blood cancer cells.
Researchers have shown a gene therapy to correct the genetic mutation that causes Danon disease is successful in pre-clinical trials.
A novel therapy, tested ex vivo, has been successful at correcting the dysfunctional body mechanism in Postural Orthostatic Tachycardia Syndrome (POTS).
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
Researchers in the United States have used particles from the tobacco mosaic virus (TMV) to produce a new much-needed malaria vaccine.
A clinical study is to be launched after researchers found that a common and inexpensive drug may be used to counteract treatment resistance in patients with AML.
This article highlights some of the most recent drug target discoveries that could be used to develop and design a treatment for pancreatic cancer.
Researchers have discovered that patients with alcoholic hepatitis had high numbers of a destructive gut bacterium and they were able to use a cocktail of phages to target and kill the bacteria, eradicating the disease.
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
Scientists in the US have developed a promising new CAR T-cell therapy that targets the BAFF-R protein, which has demonstrated superior cancer destruction to existing FDA-approved CAR-T therapies.
The memory of mice with Alzheimer's greatly improved after they were injected with two newly discovered short peptides.
A new drug discovery strategy predicts the clinical actions of new compounds to promote desired clinical responses and avoid side effects.
A potential treatment for polycystic kidney disease has shown positive results in animal testing.
Researchers have developed a new cocktail of drugs that shrink pancreatic tumours in mice by blocking pathways that cancer cells use.